Startup profile · funding coverage
Aradigm funding, valuation and investors
Benefits platform enabling sustainable employer access to cell and gene therapies.
Keep track of Aradigm
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
Amount not disclosed · 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · San Francisco, California
Investors in latest funding
Other: Andreessen Horowitz
Overview
Aradigm is a public benefit corporation that helps employers and health plans provide sustainable access to cell and gene therapies (CGTs). The platform pools risk and coordinates benefits design so patients can access approved CGTs without employers bearing unpredictable single-case catastrophic costs.
Why Aradigm is interesting
Public benefit corporation pooling CGT risk for employers and payors — founded by Will Shrank (ex-Humana, CMS, a16z venture partner) to solve million-dollar therapy affordability.
Product & use cases
Aradigm is a public benefit corporation that helps employers and health plans provide sustainable access to cell and gene therapies (CGTs).
- Enterprise platform deployment for core workflows
- Healthcare provider and health-system operations
Key facts
- Series A (2025): co-led by Frist Cressey and Morgan Health with a16z; Two Sigma Ventures and First Round named in reporting (Endpoints News)
- Seed (2024): a16z led at inception (a16z announcement)
- Model: PBC pooling CGT risk for employer-sponsored health plans (Aradigm site)
- Co-investors not in VCT directory: Frist Cressey Ventures, Morgan Health
Funding history (newest first)
Series A
2025Source: Series A (2025): co-led by Frist Cressey and Morgan Health with a16z; Two Sigma Ventures and First Round named in reporting (Endpoints News)
Investors in our directory
Funds linked from Aradigm's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Public benefit corporation pooling CGT risk for employers and payors — founded by Will Shrank (ex-Humana, CMS, a16z venture partner) to solve million-dollar therapy affordability.
Aradigm competes in healthtech, biotech-life-sciences. Incumbents have distribution; startup edge depends on product depth and buyer references. See competitors for specific tradeoffs — no invented market share claims.
-
Epic Systems incumbent
Dominant EHR incumbent.
-
Oracle Health incumbent
Enterprise EHR competitor.
-
Veeva incumbent
Life sciences cloud incumbent.
-
Dotmatics adjacent
R&D informatics.
Notable stories
- Series A (2025): co-led by Frist Cressey and Morgan Health with a16z; Two Sigma Ventures and First Round named in reporting (Endpoints News)
Industries
Related funding articles
Venture Capital Tracker pieces that cover Aradigm's financing or category context.
FAQs about Aradigm
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.